Notice of Intent to Award a Sole Source Contract to Hitachi
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Food and Drug Administration (FDA) intends to award a Sole Source firm-fixed price commercial Purchase Order to Hitachi for a critical high voltage pump. This is a Notice of Intent, not a request for competitive quotes, issued under FAR Part 6.302-1, citing only one responsible source. Firms interested in demonstrating their capability to meet this requirement must submit a statement by June 19, 2026.
Scope of Work
The requirement is for a high voltage pump, which serves as a direct replacement part for the existing Hitachi SU6600 Field Emission Scanning Electron Microscope (FE-SEM). This FE-SEM is essential for analyzing criminal and public health samples, making system reliability crucial for mission-critical operations.
Contract & Timeline
- Type: Firm-Fixed Price Commercial Purchase Order (Sole Source)
- Agency: Food and Drug Administration (FDA)
- Rationale: Hitachi is the sole manufacturer and original equipment manufacturer (OEM) of the required pump, possessing the necessary technical specifications and manufacturing processes. Market research confirmed no other compatible manufacturers.
- Capability Statement Due: June 19, 2026, 5:00 PM ET
- Published: June 4, 2026
- Place of Performance: Cincinnati, OH
Additional Notes
This is a Notice of Intent to Award a Sole Source Contract, not a request for competitive quotes. The government will review submitted capability statements to determine if requirements can be met but reserves the discretion not to compete this requirement based on responses received.
Contact Information
- Primary Point of Contact: Janice Heard (janice.heard@fda.hhs.gov, 215-717-3093)